Výsledky vyhledávání - "J R Allegretti"

P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open

Autor: J R Allegretti, K B Gecse, M V Chiorean, M Argollo, X Guo, N Lawendy, C Su, R Mundayat, J Paulissen, L Salese, P M Irving

Publikováno v: Journal of Crohn's and Colitis. 16:i446-i447

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Patients may require retreatment following treatment interruption for reasons such as adverse events or pregnancy.1 In the tofacitinib UC cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d585f054b67028c0ccb1c2a32b119b2d
https://doi.org/10.1093/ecco-jcc/jjab232.604

Zobrazit plný text záznamu

P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open

Autor: J R Allegretti, K B Gecse, M V Chiorean, M Argollo, X Guo, N Lawendy, C Su, R Mundayat, J Paulissen, L Salese, P M Irving

Publikováno v: Journal of Crohn's and Colitis. 16:i380-i381

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). In the tofacitinib UC clinical programme, patients who responded to tofacitinib, 10 mg BID during induction, and experienced treatment failu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::994846b4db57be50333e24d7908e58ee
https://doi.org/10.1093/ecco-jcc/jjab232.505

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání